Emergent BioSolutions Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated May 23, 2019, details the results of Emergent BioSolutions Inc.'s 2019 Annual Meeting of Stockholders. The meeting was held on May 23, 2019, with a record date of March 28, 2019.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A total of 47,878,139 shares were present or represented by proxy, representing approximately 93.17% of the 51,382,454 outstanding shares entitled to vote. Three proposals were considered and approved:
- Proposal 1 (Election of Directors): All four nominees were elected.
- Fuad El-Hibri: 43,422,085 For; 2,460,532 Against.
- Ronald B. Richard: 45,110,043 For; 771,046 Against.
- Kathryn C. Zoon, Ph.D.: 45,689,636 For; 193,950 Against.
- Seamus Mulligan: 43,489,886 For; 2,393,365 Against.
- Proposal 2 (Ratification of Auditors): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019, was approved with 47,455,542 votes For and 410,331 votes Against.
- Proposal 3 (Executive Compensation): The advisory vote to approve the compensation of named executive officers was approved with 44,801,685 votes For and 1,061,264 votes Against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific terms of office for the newly elected directors (Class I terms expire in 2022; Class II term expires in 2020).
- Confirm the "Against" vote percentages for directors Fuad El-Hibri and Seamus Mulligan, which were higher than the other nominees.
- Review the full proxy statement referenced in the filing for detailed descriptions of the proposals and executive compensation specifics.